FN2 Earnings Intelligence
Teva Pharmaceutical Industries Limited financials
Teva Pharmaceutical Industries Limited (TEVA) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $2,165 | $2,801 | $3,226 | $3,300 | $3,556 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $15,878 | $14,925 | $15,846 | $16,544 | $17,258 |
| % Growth | -4.7% | -6.0% | 6.2% | 4.4% | 4.3% |
| Gross Profit | $7,594 | $6,973 | $7,645 | $8,064 | $8,938 |
| % Margin | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| EBITDA | $3,046 | -$791 | $1,586 | $756 | $3,159 |
| % Margin | 19.2% | -5.3% | 10.0% | 4.6% | 18.3% |
| Net Income | $417 | -$2,353 | -$559 | -$1,639 | $1,410 |
| % Margin | 2.6% | -15.8% | -3.5% | -9.9% | 8.2% |
| Diluted EPS | $0.38 | -$2.12 | -$0.50 | -$1.45 | $1.21 |
| % Growth | 110.4% | -657.9% | 76.4% | -190.0% | 183.4% |
| Operating Cash Flow | $798 | $1,590 | $1,368 | $1,247 | $1,649 |
| CapEx | $562 | $548 | $526 | $498 | $501 |
| Free Cash Flow | $236 | $1,042 | $842 | $749 | $1,148 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $15,878 | $14,925 | $15,846 | $16,544 | $17,258 |
| Gross Profit | $7,594 | $6,973 | $7,645 | $8,064 | $8,938 |
| EBITDA | $3,046 | -$791 | $1,586 | $756 | $3,159 |
| Net Income | $417 | -$2,353 | -$559 | -$1,639 | $1,410 |
| Diluted EPS | $0.38 | -$2.12 | -$0.50 | -$1.45 | $1.21 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2,165 | $2,801 | $3,226 | $3,300 | $3,556 |
| Short-term Debt | $1,426 | $2,109 | $1,672 | $1,781 | $1,820 |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $798 | $1,590 | $1,368 | $1,247 | $1,649 |
| Capital Expenditure | $562 | $548 | $526 | $498 | $501 |
| Free Cash Flow | $236 | $1,042 | $842 | $749 | $1,148 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | -4.7% | -6.0% | 6.2% | 4.4% | 4.3% |
| Gross Margin | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| EBITDA Margin | 19.2% | -5.3% | 10.0% | 4.6% | 18.3% |
| Net Margin | 2.6% | -15.8% | -3.5% | -9.9% | 8.2% |
| FCF Margin | 1.5% | 7.0% | 5.3% | 4.5% | 6.7% |
| Diluted EPS Growth | 110.4% | -657.9% | 76.4% | -190.0% | 183.4% |
Get the TEVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.